Randomized trial of atopaxar in the treatment of patients with coronary artery disease:the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

Wiviott, Stephen D, Flather, Marcus D, O'Donoghue, Michelle L, Goto, Shinya, Fitzgerald, Desmond J, Cura, Fernando, Aylward, Philip, Guetta, Victor, Dudek, Dariusz, Contant, Charles F, Angiolillo, Dominick J, Bhatt, Deepak L and , LANCELOT-CAD Investigators (2011) Randomized trial of atopaxar in the treatment of patients with coronary artery disease:the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation, 123 (17). pp. 1854-63. ISSN 0009-7322

Full text not available from this repository. (Request a copy)

Abstract

Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.

Item Type: Article
Uncontrolled Keywords: aged,biological markers,blood platelets,coronary artery disease,dose-response relationship, drug,female,hemorrhage,humans,imines,male,middle aged,platelet activation,platelet aggregation inhibitors,pyridines,receptors, thrombin
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:12
Last Modified: 21 Apr 2020 22:33
URI: https://ueaeprints.uea.ac.uk/id/eprint/46238
DOI: 10.1161/CIRCULATIONAHA.110.001404

Actions (login required)

View Item View Item